NEW
YORK, Oct. 4, 2023 /PRNewswire/ -- Immunic,
Inc. (Nasdaq: IMUX), a biotechnology company
developing a clinical pipeline of orally administered, small
molecule therapies for chronic inflammatory and autoimmune
diseases, today announced participation in the following scientific
conferences in October:
- October 11-13: MSMilan2023: The 9th Joint
ECTRIMS-ACTRIMS Meeting. Robert J.
Fox, MD, Staff Neurologist, Mellen Center for Multiple
Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland
Clinic, Cleveland, Ohio, will
present data from Immunic's phase 2 EMPhASIS trial of vidofludimus
calcium (IMU-838) in relapsing-remitting multiple sclerosis (MS),
in an ePoster at this meeting in Milan,
Italy. The poster presentation will be accessible on the
"Events and Presentations" section of Immunic's website at:
https://ir.imux.com/events-and-presentations.
- Title: Reduction in Neurofilament Light Chain by
Vidofludimus Calcium: The EMPhASIS Study
- Abstract Number: 1290
- ePoster Number: P1390
- Poster Session: Imaging and non-imaging biomarkers
- Fluid Biomarkers
- October 14-17: UEG (United European Gastroenterology)
Week 2023. Immunic's clinical team will attend this conference
in Copenhagen, Denmark, and
present two abstracts, one in a moderated poster session and the
other during an oral presentation. The presentations will be
accessible on the "Events and Presentations" section of Immunic's
website at: https://ir.imux.com/events-and-presentations.
- Title: First in Human Trial of IMU-856, An
Orally Available Epigenetic Modulator of Barrier Regeneration for
the Treatment of Celiac Disease
- Abstract Number: AS-UEG-2023-01180
- Poster Number: MP147
- Presenting Author: Franziska Burianek, MD, Senior Medical Director,
Immunic
- Poster Session: Coeliac disease
- Location: Moderated Posters, Poster Stage 3
- Date: Sunday, October 15,
2023
- Time: 5:48 – 5:54 pm
CET
- Title: Efficacy and Safety of Vidofludimus Calcium
(IMU-838) In Patients With Moderately to Severely Active Ulcerative
Colitis (UC): Results From the Prospective Placebo-Controlled Phase
2 CALDOSE-1 Trial
- Abstract Number: AS-UEG-2023-01648
- Presentation Number: OP106
- Presenting Author: Geert R. D'Haens, MD, PhD, Full
Professor, AGEM - Amsterdam Gastroenterology Endocrinology
Metabolism and Gastroenterology and Hepatology, Amsterdam
University Medical Centers, The
Netherlands
- Presentation Session: The new kids on the block in
IBD: Part 2
- Location: Abstract Session, A3
- Date: Monday, October 16,
2023
- Time: 3:18 – 3:30 pm
CET
- October 23-25: Global Pharmaceutical Regulatory Affairs
Summit. Darius-Jean Namdjou, PhD, Head of Regulatory Affairs
and Pharmacovigilance at Immunic, will speak during two sessions at
this summit in Brussels, Belgium.
- Title: A Strategic Example: Implementation of
the Clinical Trials Regulation
- Session: Regulatory Guidances and Legislative
Landscape
- Date: Monday, October 23, 2023
- Time: 11:10 – 11:50 am
CET
- Title: Big Picture Panel: The Future of
Legislation, Regulatory Affairs & Regulatory
Operations
- Session: Regulatory Guidances and Legislative
Landscape
- Date: Monday, October 23, 2023
- Time: 4:45 – 5:30 pm CET
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing
a clinical pipeline of orally administered, small molecule
therapies for chronic inflammatory and autoimmune diseases. The
company's lead development program, vidofludimus calcium (IMU-838),
is currently in phase 3 and phase 2 clinical trials for the
treatment of relapsing and progressive multiple sclerosis,
respectively, and has shown therapeutic activity in phase 2
clinical trials in patients suffering from relapsing-remitting
multiple sclerosis and moderate-to-severe ulcerative colitis.
Vidofludimus calcium combines neuroprotective effects, through its
mechanism as a first-in-class nuclear receptor related 1 (Nurr1)
activator, with additional anti-inflammatory and anti-viral
effects, by selectively inhibiting the enzyme dihydroorotate
dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6
(SIRT6), is intended to restore intestinal barrier function and
regenerate bowel epithelium, which could potentially be applicable
in numerous gastrointestinal diseases, such as celiac disease,
where it is currently in preparations for a phase 2 clinical trial.
IMU-381, which currently is in preclinical testing, is a next
generation molecule being developed to specifically address the
needs of gastrointestinal diseases. For further information, please
visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements" that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
facts, included in this press release regarding strategy, future
operations, future financial position, future revenue, projected
expenses, sufficiency of cash, expected timing, development and
results of clinical trials, prospects, plans and objectives of
management are forward-looking statements. Examples of such
statements include, but are not limited to, statements relating to
management's and employee's participation in scientific
conferences. Immunic may not actually achieve the plans, carry out
the intentions or meet the expectations or projections disclosed in
the forward-looking statements and you should not place undue
reliance on these forward-looking statements. Such statements are
based on management's current expectations and involve substantial
risks and uncertainties. Actual results and performance could
differ materially from those projected in the forward-looking
statements as a result of many factors, including, without
limitation, the COVID-19 pandemic, increasing inflation, impacts of
the Ukraine – Russia conflict on planned and ongoing
clinical trials, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient financial and other resources to meet
business objectives and operational requirements, the fact that the
results of earlier preclinical studies and clinical trials may not
be predictive of future clinical trial results, the protection and
market exclusivity provided by Immunic's intellectual property,
risks related to the drug development and the regulatory approval
process and the impact of competitive products and technological
changes. A further list and descriptions of these risks,
uncertainties and other factors can be found in the section
captioned "Risk Factors," in the company's Annual Report on Form
10-K for the fiscal year ended December 31,
2022, filed with the SEC on February
23, 2023, and in the company's subsequent filings with the
Securities and Exchange Commission. Copies of these filings are
available online at www.sec.gov or ir.imux.com/sec-filings. Any
forward-looking statement made in this release speaks only as of
the date of this release. Immunic disclaims any intent or
obligation to update these forward-looking statements to reflect
events or circumstances that exist after the date on which they
were made. Immunic expressly disclaims all liability in respect to
actions taken or not taken based on any or all the contents of this
press release.
Contact Information
Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-scientific-conferences-in-october-301944377.html
SOURCE Immunic, Inc.